CytomX Therapeutics, Inc. (CTMX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$23.78M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$19.67M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$15.77M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.29M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$23.78M | (m) | $1.42M | (m) | $0.00* | -$18.07M* | (m) | $17.60M | (m) | $60.00K |
| 2026-03-31 | Reported | (m) | -$19.67M | (m) | $10.26M | (m) | $0.00 | -$25.55M | (m) | $19.24M | (m) | $59.00K |
| 2025-09-30 | Reported | (m) | -$15.77M | (m) | $5.96M | (m) | -$127.00K* | -$15.55M* | (m) | $15.30M | (m) | $58.00K |
| 2025-06-30 | Reported | (m) | -$1.29M | (m) | $18.66M | (m) | $27.00K* | -$15.75M* | (m) | $13.32M | (m) | $63.00K |
| 2025-03-31 | Reported | (m) | $22.62M | (m) | $50.92M | (m) | $119.00K | -$21.04M | (m) | $18.87M | (m) | $62.00K |
| 2024-09-30 | Reported | (m) | $4.11M | (m) | $33.43M | (m) | $19.00K* | -$20.73M* | (m) | $21.37M | (m) | $61.00K |
| 2024-06-30 | Reported | (m) | -$8.45M | (m) | $25.11M | (m) | $96.00K* | -$19.55M* | (m) | $25.17M | (m) | $51.00K |
| 2024-03-31 | Reported | (m) | $11.66M | (m) | $41.46M | (m) | $115.00K | -$26.05M | (m) | $22.05M | (m) | $49.00K |
| 2023-09-30 | Reported | (m) | $3.12M | (m) | $26.38M | (m) | $9.00K* | -$18.24M* | (m) | $16.45M | (m) | $2.82M |
| 2023-06-30 | Reported | (m) | -$3.35M | (m) | $24.72M | (m) | $517.00K* | -$25.18M* | (m) | $20.67M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$5.65M | (m) | $23.50M | (m) | $48.00K | $9.35M | (m) | $21.18M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$29.71M | (m) | $11.15M | (m) | $410.00K* | -$33.84M* | (m) | $30.37M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$30.05M | (m) | $12.85M | (m) | $412.00K* | -$34.24M* | (m) | $31.16M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$32.06M | (m) | $9.04M | (m) | $736.00K | -$41.31M | (m) | $30.56M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$34.90M | (m) | $11.13M | (m) | (m) | (m) | (m) | $36.58M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$31.04M | (m) | $9.19M | (m) | $268.00K* | -$29.70M* | (m) | $29.14M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$26.70M | (m) | $8.79M | (m) | $114.00K* | -$28.20M* | (m) | $26.10M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$23.40M | (m) | $8.20M | (m) | $982.00K | -$29.94M | (m) | $22.37M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$24.07M | (m) | $7.08M | (m) | (m) | (m) | (m) | $22.01M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$25.22M | (m) | $7.47M | (m) | $778.00K* | -$24.68M* | (m) | $24.05M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$25.76M | (m) | $6.99M | (m) | $37.00K* | $97.10M* | (m) | $24.07M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$5.49M | (m) | $46.90M | (m) | $1.05M | -$49.74M | (m) | $42.81M | (m) | -$13.91M |
| 2019-09-30 | Reported | (m) | -$25.72M | (m) | $10.71M | (m) | $628.00K* | -$23.32M* | (m) | $27.97M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$31.23M | (m) | $9.01M | (m) | $331.00K* | -$48.65M* | (m) | $30.84M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$16.57M | (m) | $29.48M | (m) | $1.83M | -$39.03M | (m) | $36.38M | (m) | -$6.00K |
| 2018-12-31 | Reported | (m) | -$25.81M | (m) | $11.47M | (m) | (m) | (m) | (m) | (m) | (m) | $8.91M |
| 2018-09-30 | Reported | (m) | -$23.18M | (m) | $12.51M | (m) | $1.05M* | -$5.55M* | (m) | $27.55M | (m) | $2.50M |
| 2018-06-30 | Reported | (m) | -$13.26M | (m) | $21.34M | (m) | $868.00K* | -$26.62M* | (m) | $25.55M | (m) | $1.79M |
| 2018-03-31 | Reported | (m) | -$15.63M | (m) | $14.18M | (m) | $751.00K | -$14.61M | (m) | $22.46M | (m) | $1.10M |
| 2017-09-30 | Reported | (m) | -$11.03M | (m) | $24.14M | (m) | $57.00K* | -$5.74M* | (m) | $28.92M | (m) | -$19.00K |
| 2017-06-30 | Reported | (m) | -$25.37M | (m) | $8.75M | (m) | $324.00K* | (m) | (m) | $28.08M | (m) | $26.00K |
| 2017-03-31 | Reported | (m) | -$8.61M | (m) | $11.65M | (m) | $944.00K | (m) | (m) | $14.58M | (m) | -$1.00K |
| 2016-09-30 | Reported | (m) | -$14.92M | (m) | (m) | (m) | $863.00K* | (m) | (m) | $13.34M | (m) | $1.00K |
| 2016-06-30 | Reported | (m) | -$14.26M | (m) | (m) | (m) | $384.00K* | (m) | (m) | $12.71M | (m) | $3.00K |
| 2016-03-31 | Reported | (m) | -$16.18M | (m) | (m) | (m) | $327.00K | (m) | (m) | $13.37M | (m) | $3.00K |
| 2015-09-30 | Reported | (m) | -$11.27M | (m) | (m) | (m) | $363.00K* | (m) | (m) | $9.16M | (m) | $3.00K |
| 2015-06-30 | Reported | (m) | -$5.54M | (m) | (m) | (m) | $794.00K* | (m) | (m) | $5.03M | (m) | $5.00K |
| 2015-03-31 | Reported | (m) | -$4.87M | (m) | (m) | (m) | $255.00K | (m) | (m) | $4.66M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$3.46M | (m) | (m) | (m) | (m) | (m) | (m) | $3.92M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$22.36M | (m) | $76.20M | (m) | $220.00K | -$75.59M | (m) | $68.73M | (m) | $238.00K |
| 2024-12-31 | Reported | (m) | $25.00M | (m) | $138.10M | (m) | $310.00K | -$86.23M | (m) | $83.38M | (m) | $224.00K |
| 2023-12-31 | Reported | (m) | -$6.48M | (m) | $101.21M | (m) | $840.00K | -$56.03M | (m) | $77.68M | (m) | $3.89M |
| 2022-12-31 | Reported | (m) | -$101.33M | (m) | $53.16M | (m) | $1.74M | -$110.79M | (m) | $111.65M | (m) | $0.00 |
| 2022-09-30 | Rolling | (m) | -$126.73M* | (m) | $44.17M* | (m) | (m) | (m) | (m) | $128.66M* | (m) | (m) |
| 2022-06-30 | Rolling | (m) | -$128.06M* | (m) | $42.21M* | (m) | (m) | (m) | (m) | $127.44M* | (m) | (m) |
| 2022-03-31 | Rolling | (m) | -$124.70M* | (m) | $38.16M* | (m) | (m) | (m) | (m) | $122.38M* | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$116.04M | (m) | $37.31M | (m) | $1.61M | -$119.03M | (m) | $114.19M | (m) | $0.00 |
| 2021-12-31 | Rolling | (m) | -$116.04M* | (m) | $37.31M* | (m) | (m) | (m) | (m) | $114.19M* | (m) | (m) |
| 2021-09-30 | Rolling | (m) | -$105.21M* | (m) | $33.26M* | (m) | (m) | (m) | (m) | $99.62M* | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$99.39M* | (m) | $31.54M* | (m) | (m) | (m) | (m) | $94.53M* | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$98.45M* | (m) | $29.73M* | (m) | (m) | (m) | (m) | $92.49M* | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$80.54M | (m) | $68.43M | (m) | $2.31M | $5.26M | (m) | $112.94M | (m) | -$13.91M |
| 2020-12-31 | Rolling | (m) | -$80.54M* | (m) | $68.43M* | (m) | (m) | (m) | (m) | $112.94M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$141.48M | (m) | $26.90M | (m) | $3.50M | -$140.48M | (m) | $131.62M | (m) | -$427.00K |
| 2019-09-30 | Rolling | (m) | -$99.33M* | (m) | $60.68M* | (m) | (m) | (m) | (m) | (m) | (m) | $8.91M* |
| 2019-06-30 | Rolling | (m) | -$96.79M* | (m) | $62.48M* | (m) | (m) | (m) | (m) | (m) | (m) | $11.41M* |
| 2019-03-31 | Rolling | (m) | -$78.81M* | (m) | $74.80M* | (m) | (m) | (m) | (m) | (m) | (m) | $13.20M* |
| 2018-12-31 | Reported | (m) | -$77.87M | (m) | $59.50M | (m) | $3.79M | -$75.52M | (m) | $103.87M | (m) | $14.30M |
| 2018-12-31 | Rolling | (m) | -$77.88M* | (m) | $59.50M* | (m) | (m) | (m) | (m) | (m) | (m) | $14.30M* |
| 2017-12-31 | Reported | (m) | -$46.26M | (m) | $71.62M | (m) | $1.56M | $170.37M | (m) | $92.28M | (m) | -$513.00K |
| 2016-12-31 | Reported | (m) | -$59.59M | (m) | $12.85M | (m) | $2.18M | -$2.03M | (m) | $54.76M | (m) | -$19.00K |
| 2015-12-31 | Reported | (m) | -$33.20M | (m) | (m) | (m) | $1.59M | (m) | (m) | $28.36M | (m) | $10.00K |
| 2014-12-31 | Reported | (m) | -$29.77M | (m) | (m) | (m) | $1.66M | (m) | (m) | $28.30M | (m) | $10.00K |
| 2013-12-31 | Reported | (m) | -$14.96M | (m) | (m) | (m) | $732.00K | (m) | (m) | $10.89M | (m) | $10.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |